source
- LEO Pharma spends $435 million to acquire rare-disease skin drug dersimelagonLEO Pharma announced it will pay $435 million to buy the rights to dersimelagon, an oral MC1R agonist originally developed by Tanabe Pharma. The drug has completed Phase 3 trials for two rare phot…
- Biotech funding rebound set to boost CDMO demand by early 2027Analysts note that demand for pharma services has historically lagged behind biotech funding, but a recent surge in venture capital is expected to drive activity for contract development and manufa…